.png?width=1800&height=600&name=MicrosoftTeams-image%20(82).png)
1 min read
At KBI Biopharma, our PUREplatform™ is everything you need to make a protein. Catered to your needs, our service package contains plasmids, strains,…
2 min read
Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors,…
2 min read
Biopharmaceutical companies are increasingly seeking service providers to help them reduce biologics manufacturing risks while increasing the speed…
2 min read
Over the past 30 years, biologic therapeutics have significantly transformed treatment options for millions of individuals who face a range of…
2 min read
Geneva, Switzerland, May 11, 2022 – Selexis SA, a JSR Life Sciences Company, announced today that Great Place to Work® has designated the Company…
3 min read
Third Biosimilar to Reach the Market Under Selexis/Generium Commercial License Agreements
2 min read
Geneva, Switzerland, and Paris, France, January 19, 2022 – Selexis SA, a JSR Life Sciences company, and Inotrem SA, an advanced clinical-stage…
3 min read
Hemogenyx Pharmaceuticals will leverage Selexis’ SUREtechnology Platform™ of protein expression technologies and modular workflows
2 min read
Tallac Will Draw on Selexis’ Best-in-Class Cell Line Development Technologies Under New Commercial License and Service Agreements
2 min read
Geneva, Switzerland, March 18, 2021 – Selexis SA, a JSR Life Sciences company, and SpyBiotech, a biotechnology company with a novel vaccine platform,…
